Tirzepatide Reduces risk of Heart Attack and hospitalisation due to Infection in Type 2 Diabetes: Study Written By Dr. Kamal Kant Kohli8 Aug 2026 9:00 AM ISTA large U.S. database study found that tirzepatide (Mounjaro) significantly reduced the risk of heart attacks and hospitalization due to infections by...
GLP-1 drug linked to heart benefits for high-risk patients :Study Written By Dr. Kamal Kant Kohli6 Aug 2026 7:30 AM ISTAdding the GLP-1 receptor agonist drug tirzepatide (marketed as Mounjaro) to standard care for patients with type 2 diabetes and heart disease is...
Newer obesity drugs linked to fewer alcohol-related hospitalizations for people with alcohol dependence: Study Written By Dr. Kamal Kant Kohli30 July 2026 9:00 PM ISTUse of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder was associated with a...
Retatrutide Produces More Than 20% Weight Loss in Phase 3 Trials Written By Dr Kartikeya Kohli25 July 2026 12:45 PM ISTTopline results from two phase 3 trials showed that retatrutide produced substantial weight loss in adults with obesity, including those with type 2...
Tirzepatide Shows Promise for Weight Loss and Reduced Insulin Needs in Type 1 Diabetes: Study Written By Dr. Shravani Dali15 July 2026 10:00 AM ISTResearchers have found in recent study that among adults with type 1 diabetes (T1D) who are overweight or obese, adjunctive treatment with...
Weight loss treatments linked to lower risk of obesity-related cancers in people without diabetes: Study Written By Dr. Kamal Kant Kohli30 Jun 2026 8:45 PM ISTA study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk...
Tirzepatide may change how the body uses energy, suggests research Written By Dr. Kamal Kant Kohli28 Jun 2026 9:30 PM ISTTirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research,...
Beyond GLP-1s: The next chapter of obesity care Written By Dr. Kamal Kant Kohli25 Jun 2026 9:00 AM ISTThe rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are...
Tirzepatide May Boost Energy Burning by Activating Brown Fat: Study Written By Dr Kartikeya Kohli24 Jun 2026 12:15 PM ISTSlovenia: A small study presented at ENDO 2026 has revealed that tirzepatide may increase the body's energy expenditure by activating brown adipose...
Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide: Study Written By Dr. Kamal Kant Kohli22 Jun 2026 9:00 AM ISTOne of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes...
India's GLP-1 Market Nears Rs 2,000 Crore as Semaglutide Boom Slows, Tirzepatide Regains Momentum Written By Susmita Roy21 Jun 2026 12:45 PM ISTNew Delhi: India's rapidly expanding GLP-1 agonist market is entering a new phase of maturity, with the explosive growth triggered by semaglutide...
Low-Dose Tirzepatide Improves Metabolic Health in Psoriasis and Obesity, suggests study Written By Jacinthlyn Sylvia18 Jun 2026 10:15 PM ISTA new study published in the journal of Dermatology and Therapy showed that treatment with low-dose tirzepatide was linked to clinically significant...
